

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**  
**HIGHLY SPECIALISED TECHNOLOGIES EVALUATION PROGRAMME**

**Equality impact assessment – Scoping**

**Onasemnogene abeparvovec for treating pre-symptomatic  
spinal muscular atrophy (MAA partial review of HST 15)  
[ID4015]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees highlighted that, because onasemnogene abeparvovec would be provided at a limited number of highly specialist centres, there was the potential for issues of equity of access based on geographic location.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Access to highly specialist centres is an implementation issue; it is not an equality issue to be considered by the committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope are needed.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No changes to the Stakeholder list are needed.

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 7 June 2022